BioXcel Therapeutics Inc. (BTAI) is expected to release topline data from its phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, dubbed SERENITY At-Home, this month. The stock leads premarket gainers today on growing investor anticipation.
The following is the list of biotech stocks making big moves in premarket hours.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com